Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: An observational study

Critical Reviews in Oncology/Hematology

Volumn 68, Issue 2, 2008, Pages 178-182

  Locher, Christophe ^a   Fabre Guillevin, Elizabeth ^a,b   Brunetti, Francesco ^a   Auroux, Jean ^a   Delchier, Jean Charles ^a   Piedbois, Pascal ^a,b   Zelek, Laurent ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b European Association for Research in Oncology (AERO)   (France)

Author keywords

Elderly; Gemcitabine; Pancreas cancer; Prospective study

Indexed keywords

GEMCITABINE;

ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; CANCER PATIENT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; PALLIATIVE CARE; PANCREATIC NEOPLASMS;

EID: 52149099441     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.06.010     Document Type: Review

References (17)

1. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics. CA Cancer J Clin 52 (2002) 23-47
2. Li D., Xie K., Wolff R., and Abbruzzese J.L. Pancreatic cancer. Lancet 363 (2004) 1049-1057
3. Glimelius B., Hoffman K., Sjoden P.O., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7 (1996) 593-600
4. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
5. Balducci L., and Extermann M. Management of cancer in the older person: a practical approach. Oncologist 5 (2000) 224-237
6. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
7. Tempero M., Plunkett W., Ruiz van Haperen V., et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21 (2003) 3402-3408
8. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
9. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1980) 373-383
10. Ershler W.B. Cancer: a disease of the elderly. J Support Oncol 4 Suppl 2 (2003) 5-10
11. Repetto L., Venturino A., Fratino L., et al. Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 39 (2003) 870-880
12. Rao A.V., Seo P.H., and Cohen H.J. Geriatric assessment and comorbidity. Semin Oncol 31 (2004) 149-155
13. Balducci L., and Beghe C. Pharmacology of chemotherapy in the older cancer patient. Cancer Control 6 (1999) 466-470
14. Krzyzanowska M.K., Weeks J.C., and Earle C.C. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol 21 (2003) 3409-3414
15. Mallinson C.N., Rake M.O., Cocking J.B., et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicenter trial. Br Med J 281 (1980) 1589-1591
16. Palmer K.R., Kerr M., Knowles G., Cull A., Carter D.C., and Leonard R.C. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81 (1994) 882-885
17. Gridelli C., Aapro M., Ardizzoni A., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 23 (2005) 3125-3137